Exp Clin Endocrinol Diabetes 2014; 122(03): 173-178
DOI: 10.1055/s-0033-1363977
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Effect of Benfotiamine on Mu-opioid Receptor Mediated Antinociception in Experimental Diabetes

C. Nacitarhan
1   Pharmacology Department, School of Medicine, Akdeniz University, Antalya, Turkey
E. Minareci
1   Pharmacology Department, School of Medicine, Akdeniz University, Antalya, Turkey
G. Sadan
1   Pharmacology Department, School of Medicine, Akdeniz University, Antalya, Turkey
› Author Affiliations
Further Information

Publication History

received 07 August 2013
first decision 13 December 2013

accepted 18 December 2013

Publication Date:
18 March 2014 (online)


Diabetic neuropathy is a prevalent, disabling disorder. Currently, the only treatments available to patients with diabetic neuropathy are glucose control and pain management. B vitamin present neuroprotective effects, which are suggested to be related to their analgesic action in various models of neuropathic pain. According to our literature knowledge there is no report about antinociceptive effects of thiamine as benfotiamine and opioids together in diabetic mice. The purpose of this study was to determine the effects of benfotiamine on the antinociception produced by mu-opioid receptor agonist fentanyl in diabetic mice. The effects of benfotiamine on antinociception produced by fentanyl in diabetic mice were studied in 4 groups. Antinociceptive effect was determined with tail flick, hot plate and formalin test. Our results showed that, mu-opioid agonist fentanyl in benfotiamine applied diabetic group caused more potent antinociceptive effect than in diabetic group without benfotiamine treatment. In brief benfotiamine supplement in diet did not bring out antinociceptive effect itself, but during development of STZ diabetes, benfotiamine replacement increased the antinociceptive effect of fentanyl in mice tail-flick test. This effect is probably due to the replacement of benfotiamine efficiency occuring in diabetes mellitus. Finally, we suppose that oral benfotiamine replacement therapy may be useful to ameliorate analgesic effect of mu-opioid agonists on neuropathic pain in diabetic case.

  • References

  • 1 Gale EAM. The discovery of type 1 diabetes. Diabetes 2001; 50: 217-226
  • 2 Centers for disease control and preventation . National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Diseases Control and Preventation; 2011
  • 3 Vincent AM, Callaghan BC, Smith AL et al. Diabetic Neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573-583
  • 4 Kamenov ZA, Traykov LD. Diabetic somatic neuropathy. Adv Exp Med Biol 2012; 771: 155-175
  • 5 Callaghan BC, Cheng HT, Stables CL et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521-534
  • 6 Bril V, England J, Franklin GM et al. Evidence-based guideline: treatment of painful diabetic neuropathy: Report of the Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical medicine and Rehabilitation. Neurology 2011; 76: 1758-1766
  • 7 Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005; 3: CD005454
  • 8 Sindrup SH, Otto M, Finnerup NB et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399-409
  • 9 Bril V. Treatments for diabetic neuropathy. J Peripher Ner Syst 2012; 17 (Suppl. 02) 22-27
  • 10 Wernicke JF, Pritchett YL, D’Souza DN et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-1420
  • 11 Kadiroglu AK, Sit D, Kayabası H et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22: 241-245
  • 12 Agrawal RP, Goswami J, Jain S et al. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract 2009; 83: 371-378
  • 13 Kukkar A, Bali A, Singh N et al. Implications and mechanisms of action of gabapentin in neuropathic pain. Arch Pharm Res 2013; DOI: 10.1007/s12272-013-0057-y.
  • 14 Vinik AI, Tuchman M, Safirstein B et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007; 128: 169-179
  • 15 Yamamoto H, Shimoshige Y, Yamaji T et al. Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats. Neuropharmacology 2009; 57: 403-408
  • 16 Wright JM, Oki JC, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997; 31: 29-34
  • 17 Gong YH, Yu XR, Liu HL et al. Antinociceptive effects of combination of tramadol and acetaminophen on painful diabetic neuropathy in streptozotocin-induced diabetic rats. Acta Anaesthesiol Taiwan 2011; 49: 16-20
  • 18 Harati Y, Gooch C, Swenson M et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846
  • 19 Ertas M, Sagduyu A, Arac N et al. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 1998; 75: 257-259
  • 20 Pitel S, Raccah D, Gerbi A et al. At low doses, a gamma-linolenic acid-lioic acid conjugate is more effective than a docosahexaenoic acid-enriched phospholipids in preventing neuropathy in diabetic rats. J Nutr 2007; 137: 368-372
  • 21 Khalil H. painful diabetic neuropathy management. Int J Evid Based Healthc 2013; 11: 77-79
  • 22 Shaibani AI, Pope LE, Thisted R et al. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. Pain Med 2012; 13: 243-254
  • 23 Forst T, Pohlmann T, Kunt T et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol 2002; 39: 1-6
  • 24 Bosi E, Conti M, Vermigli C et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005; 48: 817-823
  • 25 Kasuya D. Acupuncture for painful diabetic neuropathy. Rinsho Shinkeigaku 2012; 52: 1290-1293
  • 26 Granados-Soto V, Sanchez-Raminez G, la Torre MR et al. Effect of diclofenac on the antiallodynic activity of vitamin B12 in a neuropathic pain model in the rat. Proc West Pharmacol Soc 2004; 47: 92-94
  • 27 Bernstein AL, Dinesen JS. Brief communication: effect of pharmalogical doses of vitamin B6 on carpal tunnel syndrome, electroencephalographic results, and pain. J Am Coll Nutr 1993; 12: 73-76
  • 28 Wyatt KM, Dimmock PW, Jopnes PW et al. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. Br Med J 1999; 318: 1375-1381
  • 29 Mibielli MA, Nunes CP, Cohen JC et al. Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin. Proc West Pharmacol Soc 2010; 53: 5-12
  • 30 Mibielli MA, Geller M, Cohen JC et al. Diclofenac plus B vitamins versus diclofenac monotherapy in lumbago: the DOLOR study. Curr Med Res Opin 2009; 25: 2589-2599
  • 31 Kopruszinski CM, Reis RC, Chichorro JG. B vitamins relieve neuropathic pain behaviours induced by infraorbital nerve constricition in rats. Life Sci 2012; 91: 1187-1195
  • 32 Jolivalt CG, Mizisin LM, Nelson A et al. B vitamins alleviate indices of neuropathic pain in diabetic rats. Eur J Pharmacol 2009; 612: 41-47
  • 33 Eyigor C, Uyar M, Pırıldar S et al. Combination therapy in treatment of peripheral diabetic neuropathy with severe pain in an adolescent patient. Paediatr anaesth 2009; 19: 193-194
  • 34 Zurek JR, Nadeson R, Goodchild CS. Spinal and supraspinal components of opioid antinociception in streptozocin induced diabetic neuropathy in rats. Pain 2001; 90: 57-63
  • 35 Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol 2006; 530: 48-53
  • 36 Kuraishi Y, Harada H, Aratani S. Separate involvement of the spinal noradrenergic and serotonergic systems in morphine analgesia: the differences in mechanical and thermal analgesic tests. Brain Research 1983; 273: 245-252
  • 37 Feldman EL, Russell JW, Sullivan KA et al. New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 1999; 12: 553-563
  • 38 Verrotti A, Giuva T, Morgese G et al. New trends in the etiopathogenesis of diabetic peripheral neuropathy. J Child Neurol 2001; 16: 389-394
  • 39 Aley KO, Levine JD. Rapid onset pain induced by intravenous streptozocin in the rat. J Pain 2001; 2: 146-150
  • 40 Ohsawa M, Kamei J. Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 1999; 372: 221-228
  • 41 Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1998; 33: 11-23
  • 42 Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993; 53: 81-88
  • 43 Courteix C, Bardin M, Chantelauze C et al. Study of the sensivity of the diabetes-induced pain model in rats toa range of analgesics. Pain 1994; 57: 153-160
  • 44 Chen SR, Sweigart KL, Lakoski JM et al. Functional mu opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats. Anesthesiology 2002; 97: 1602-1608
  • 45 Shaqura M, Khalefa BI, Shakibaei M et al. Reduced number, g protein coupling, and antinociceptive efficacy of spinal mu-opioid receptors in diabetic rats are reversed by nerve growth factor. J Pain 2013; 14: 720-730
  • 46 Courteix C, Bourget P, Caussade F et al. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?. J Pharmacol Exp Ther 1998; 285: 63-70
  • 47 Rabbani N, Thornalley PJ. Emerging role of thiamine therapy for preventation and treatment of early-stage diabetic nephropathy. Diabetes Obes Metab 2011; 13: 577-583
  • 48 Gastaldi G, Coya E, Verri A et al. Transport of thiamine in rat renal brush border membrane vesicles. Kidney Int 2002; 57: 2043-2054
  • 49 Page GLJ, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. Int J Clin Pract 2011; 65: 6684-6909
  • 50 Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164-2170
  • 51 Vindedzis SA, Stanton KG, Sherriff JL et al. Thiamine deficiency in diabetes – is diet relevant?. Diab Vasc Dis Res 2008; 5: 215
  • 52 Saito N, Kimura M, Kuchiba A et al. Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol 1987; 33: 421-430
  • 53 Havivi E, Bar On H, Reshef A et al. Vitamins and trace metals status in non insulin dependent diabetes mellitus. Int J Vit Nutr Res 1991; 61: 328-333
  • 54 Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57
  • 55 Koivisto A, Pertovaara A. Transient receptor potential ankyrin 1(TRPA1) ion channel in the pathophysiology of peripheral diabetic neuropathy. Scan J Pain 2013; 4: 129-136
  • 56 Radu BM, Dumitrescu DI, Mustaciosu CC et al. Dual efffect of methylglyoxal on intracellular Ca+ signaling and neurite outgrowth in ouse sensory neurons. Cell Mol Neurobiol 2012; 32: 1047-1057
  • 57 Bierhaus A, Fleming T, Stoyanov S et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18: 926-933
  • 58 Striban A, Negrean M, Stratmann B et al. Benfotiamine prevents macro and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071
  • 59 Balakumar P, Rohilla A, Krishan P et al. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 2010; 61: 482-488
  • 60 Cameron NE, Gibson TM, Nangle MR et al. Inhibitors of advanced glycation end product formation and neovascular dysfunction in experimental diabetes. Ann NY Acad Sci 2005; 1043: 784-792
  • 61 Stracke H, Hammes HP, Werkmann D et al. Efficacy of benfotiamine versus thiamine on function and gycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diab 2001; 109: 330-336
  • 62 Stracke H, Gaus W, Achenbach U, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomized, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116: 600-605
  • 63 Obrenovich ME, Monnier VM. Vitamin B1 blocks damage caused by hyperglycemia. Sci Aging Knowledge Environ 2003; 2003 PE6
  • 64 Tomiyasu K, Inomata K. Enzyme-cytochemical study of small ganglion cells in experimental thiamine deficiency: concerning the pain mechanism. Acta Neuropathol 1991; 81: 396-400
  • 65 Brady JA, Rock CL, Horneffer MR. Thiamin status, diuretic medications, and the management of congestive heart failure. J Am Diet Assoc 1995; 95: 541-544
  • 66 Montiel-Ruiz RM, Reyes-Garcia G, Flores-Murrieta F et al. Antinociceptive ınteraction between benfothiamine and resveratrol in capsaicin-induced licking. Proc West Pharmacol Soc 2009; 52: 67-71
  • 67 Eschalier A, Aumaitre O, Decamps A, Dordain G. A comparison of the effects of vitamin B12 and aspirin in three experimental pain models in rats and mice. Psychopharmacology 1983; 81: 228-231
  • 68 Nagai R, Shirakawa JI, Ohno RI et al. Inhibition of AGEs formation by natural products. Amino Acids 2013; DOI: 10.1007/s00726-013-1487-z.
  • 69 Beltramo E, Berrone E, Tarallo S et al. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the preventation of diabetic complications. Acta Diabetol 2008; 45: 131-141
  • 70 Varkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diab Obes Metab 2008; 10: 99-108